Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
Listen now
Description
Several new therapeutic drug classes are now available to manage lipid levels. John Wilkins, MD, MS, and Donald Lloyd-Jones, MD, ScM, of the Department of Preventive Medicine and Division of Cardiology at Northwestern University Feinberg School of Medicine, discuss the use of ezetimibe, PCSK-9 inhibitors, bempedoic acid, and icosapent ethyl to manage lipid levels in patients taking statins who require additional LDL lowering. Related Content: Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk Lipids and Lipoproteins in 2020
More Episodes
Published 03/27/24
Falls are common in adults older than 65 years and can cause substantial morbidity and mortality. JAMA Associate Editor David Simel, MD, MHS, discusses risk assessment and prevention of falls in older adults with Karin E. Ouchida, MD, of Weill-Cornell Medical University, and author Cathleen...
Published 03/27/24
Dry mouth, oral candidiasis, and recurrent aphthous ulcers are common oral conditions that may be associated with patient discomfort, decreased quality of life, and in some cases, morbidity. Author Eric T. Stoopler, DMD, of Penn Dental Medicine, discusses these 3 common oral conditions with JAMA...
Published 03/26/24